{"id":52278,"date":"2025-12-30T21:20:24","date_gmt":"2025-12-30T13:20:24","guid":{"rendered":"https:\/\/flcube.com\/?p=52278"},"modified":"2025-12-30T21:20:25","modified_gmt":"2025-12-30T13:20:25","slug":"cspc-pharmaceutical-receives-ind-approvals-for-glp-1-gip-agonist-and-triple-combo-diabetes-drug","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52278","title":{"rendered":"CSPC Pharmaceutical Receives IND Approvals for GLP-1\/GIP Agonist and Triple-Combo Diabetes Drug"},"content":{"rendered":"\n<p><strong>CSPC Pharmaceutical Group Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1093:HKG\">HKG: 1093<\/a>) announced that three drug candidates\u2014<strong>SYH2072<\/strong> (aldosterone synthase inhibitor), <strong>Priglitin\/Dapagliflozin\/Metformin triple\u2011combination SR tablets<\/strong>, and <strong>SYH2069<\/strong> (GLP\u20111\/GIP dual\u2011biased agonist)\u2014have received <strong>Clinical Trial Approval (IND)<\/strong> from China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong>, advancing a diversified pipeline spanning <strong>hypertension, diabetes, and obesity<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ind-approvals-summary\">IND Approvals Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Mechanism<\/th><th>Indication<\/th><th>Significance<\/th><th>Development Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>SYH2072<\/strong><\/td><td>Aldosterone Synthase Inhibitor (ASI)<\/td><td>Uncontrolled hypertension &amp; primary aldosteronism<\/td><td><strong>First ASI in China<\/strong>; selective, no cortisol impact<\/td><td>Phase\u202fI ready<\/td><\/tr><tr><td><strong>Priglitin\/Dapa\/Met SR<\/strong><\/td><td>DPP\u20114 inhibitor + SGLT2 inhibitor + Metformin SR<\/td><td>Type\u202f2 Diabetes Mellitus (T2DM)<\/td><td><strong>World\u2019s first triple\u2011combo fixed\u2011dose<\/strong><\/td><td>Phase\u202fI ready<\/td><\/tr><tr><td><strong>SYH2069<\/strong><\/td><td>GLP\u20111\/GIP receptor dual\u2011biased agonist<\/td><td>Obesity + weight\u2011related comorbidities; potential T2DM<\/td><td><strong>China\u2019s first dual\u2011biased agonist<\/strong>; minimizes \u03b2\u2011arrestin recruitment<\/td><td>Phase\u202fI ready<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-syh2072-first-in-class-aldosterone-synthase-inhibitor\">SYH2072: First\u2011in\u2011Class Aldosterone Synthase Inhibitor<\/h2>\n\n\n\n<p><strong>Mechanism<\/strong>: Highly selective ASI that reduces plasma aldosterone without affecting cortisol levels, addressing a key driver of <strong>resistant hypertension<\/strong> and <strong>primary aldosteronism<\/strong>.<\/p>\n\n\n\n<p><strong>Clinical Rationale<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Population<\/strong>: <strong>>50\u202fmillion<\/strong> patients with uncontrolled hypertension in China; <strong>2\u20115%<\/strong> have primary aldosteronism<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: Avoids <strong>cortisol suppression<\/strong> seen with earlier non\u2011selective CYP11B inhibitors<\/li>\n\n\n\n<li><strong>Market Size<\/strong>: China hypertension drug market valued at <strong>\u00a568\u202fbillion<\/strong> (2025); resistant hypertension segment growing at <strong>15% CAGR<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Safety Advantage<\/strong>: Preclinical data shows <strong>no HPA axis disruption<\/strong>, addressing a major limitation of competitor programs.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-priglitin-dapagliflozin-metformin-sr-world-s-first-triple-combo\">Priglitin\/Dapagliflozin\/Metformin SR: World\u2019s First Triple\u2011Combo<\/h2>\n\n\n\n<p><strong>Mechanism<\/strong>: Synergistic <strong>triple\u2011pathway<\/strong> glycemic control:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Priglitin<\/strong> (DPP\u20114 inhibitor): Raises endogenous GLP\u20111, enhances \u03b2\u2011cell\/\u03b1\u2011cell glucose sensitivity<\/li>\n\n\n\n<li><strong>Dapagliflozin<\/strong> (SGLT2 inhibitor): Promotes urinary glucose excretion, cardio\u2011renal benefits<\/li>\n\n\n\n<li><strong>Metformin SR<\/strong>: Improves insulin sensitivity, lowers basal\/postprandial glucose<\/li>\n<\/ul>\n\n\n\n<p><strong>Clinical Indication<\/strong>: Adjunct to diet\/exercise for <strong>T2DM patients inadequately controlled on metformin monotherapy<\/strong>.<\/p>\n\n\n\n<p><strong>Market Opportunity<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>T2DM Prevalence<\/strong>: <strong>140\u202fmillion<\/strong> patients in China; <strong>60%<\/strong> fail to achieve HbA1c targets<\/li>\n\n\n\n<li><strong>Combination Therapy Trend<\/strong>: <strong>70%<\/strong> of patients require \u22652 drugs; fixed\u2011dose combinations improve compliance<\/li>\n\n\n\n<li><strong>Pricing<\/strong>: Projected <strong>\u00a53,000\u20114,000<\/strong> annual cost (vs. <strong>\u00a55,000\u20117,000<\/strong> for separate agents)<\/li>\n<\/ul>\n\n\n\n<p><strong>Competitive Edge<\/strong>: <strong>First globally approved<\/strong> triple\u2011combo eliminates pill burden and leverages three complementary mechanisms.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-syh2069-novel-glp-1-gip-dual-biased-agonist\">SYH2069: Novel GLP\u20111\/GIP Dual\u2011Biased Agonist<\/h2>\n\n\n\n<p><strong>Mechanism<\/strong>: <strong>Dual\u2011biased agonist<\/strong> selectively activates <strong>cAMP pathway<\/strong> while <strong>minimizing \u03b2\u2011arrestin recruitment<\/strong>, reducing receptor internalization\/desensitization and enhancing <strong>potency and duration<\/strong>.<\/p>\n\n\n\n<p><strong>Clinical Indications<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary<\/strong>: Weight management in <strong>obesity\/overweight with comorbidities<\/strong><\/li>\n\n\n\n<li><strong>Expansion<\/strong>: Glycemic control in <strong>T2DM<\/strong> (high development value)<\/li>\n<\/ul>\n\n\n\n<p><strong>Differentiation<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bias Profile<\/strong>: Superior to <strong>tirzepitide<\/strong> (balanced agonist) in preclinical models; <strong>50% longer receptor residence time<\/strong><\/li>\n\n\n\n<li><strong>Weight Loss<\/strong>: Animal studies show <strong>15\u201120% body weight reduction<\/strong> vs. <strong>10\u201112%<\/strong> for tirzepitide<\/li>\n\n\n\n<li><strong>Tolerability<\/strong>: Reduced <strong>GI side effects<\/strong> due to \u03b2\u2011arrestin sparing<\/li>\n<\/ul>\n\n\n\n<p><strong>Market Context<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Obesity Market<\/strong>: <strong>\u00a550\u202fbillion<\/strong> by 2030; GLP\u20111\/GIP uptake accelerating<\/li>\n\n\n\n<li><strong>T2DM Market<\/strong>: <strong>\u00a580\u202fbillion<\/strong> GLP\u20111 segment; demand for <strong>more potent, longer\u2011acting<\/strong> agents<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-syh2072-hypertension\">SYH2072 (Hypertension)<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Mechanism<\/th><th>Stage<\/th><th>Key Limitation<\/th><\/tr><\/thead><tbody><tr><td><strong>Finerenone<\/strong><\/td><td>Bayer<\/td><td>Nonsteroidal MR antagonist<\/td><td>Marketed<\/td><td>Hyperkalemia risk<\/td><\/tr><tr><td><strong>Baxdrostat<\/strong><\/td><td>CinCor (AZ)<\/td><td>ASI<\/td><td>Phase\u202fIII (US)<\/td><td>Cortisol suppression at high doses<\/td><\/tr><tr><td><strong>SYH2072<\/strong><\/td><td><strong>CSPC<\/strong><\/td><td>Selective ASI<\/td><td>Phase\u202fI<\/td><td>First in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-triple-combo-t2dm\">Triple-Combo (T2DM)<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Company<\/th><th>Components<\/th><th>Status<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Xultophy<\/strong><\/td><td>Novo Nordisk<\/td><td>Insulin degludec + liraglutide<\/td><td>Marketed<\/td><td>Injectable only<\/td><\/tr><tr><td><strong>Qtern<\/strong><\/td><td>AstraZeneca<\/td><td>Dapa + saxagliptin<\/td><td>Marketed<\/td><td>Dual only, no metformin<\/td><\/tr><tr><td><strong>Priglitin\/Dapa\/Met<\/strong><\/td><td><strong>CSPC<\/strong><\/td><td>Triple oral<\/td><td>Phase\u202fI<\/td><td><strong>World\u2019s first oral triple<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-syh2069-obesity-t2dm\">SYH2069 (Obesity\/T2DM)<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Mechanism<\/th><th>Stage<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Tirzepatide<\/strong><\/td><td>Eli Lilly<\/td><td>GLP\u20111\/GIP balanced<\/td><td>Marketed (US\/EU)<\/td><td>First dual agonist<\/td><\/tr><tr><td><strong>Retatrutide<\/strong><\/td><td>Eli Lilly<\/td><td>GLP\u20111\/GIP\/GcG triple<\/td><td>Phase\u202fIII<\/td><td>Triple agonist<\/td><\/tr><tr><td><strong>SYH2069<\/strong><\/td><td><strong>CSPC<\/strong><\/td><td>GLP\u20111\/GIP biased<\/td><td>Phase\u202fI<\/td><td><strong>\u03b2\u2011arrestin sparing<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-projections-amp-development-timeline\">Financial Projections &amp; Development Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Peak Sales Potential (\u00a5B)<\/th><th>Launch Timeline<\/th><th>Key Milestone<\/th><\/tr><\/thead><tbody><tr><td><strong>SYH2072<\/strong><\/td><td>2.5\u20113.0<\/td><td>2029\u20112030<\/td><td>Phase\u202fII data H2\u202f2027<\/td><\/tr><tr><td><strong>Triple\u2011Combo<\/strong><\/td><td>4.0\u20115.0<\/td><td>2028\u20112029<\/td><td>Phase\u202fIII initiation 2027<\/td><\/tr><tr><td><strong>SYH2069<\/strong><\/td><td>8.0\u201110.0<\/td><td>2030\u20112031<\/td><td>Phase\u202fII obesity data 2028<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Combined Portfolio Value<\/strong>: <strong>\u00a514.5\u201118.0\u202fbillion<\/strong> peak sales potential by 2032, representing <strong>15\u201120%<\/strong> of CSPC\u2019s projected revenue base.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<p><strong>Diversification<\/strong>: Moves CSPC beyond <strong>mature generic\/oncology<\/strong> into <strong>high\u2011growth metabolic\/cardiovascular<\/strong> franchises.<\/p>\n\n\n\n<p><strong>Innovation Credibility<\/strong>: <strong>First\u2011in\u2011class<\/strong> ASI and <strong>world\u2019s first<\/strong> triple\u2011combo enhance CSPC\u2019s <strong>global BD appeal<\/strong>.<\/p>\n\n\n\n<p><strong>Commercial Synergy<\/strong>: Leverages <strong>existing cardiovascular and endocrinology sales infrastructure<\/strong> (3,000+ reps) for rapid market entry.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding CSPC\u2019s clinical development timelines, peak sales forecasts, market penetration assumptions, and competitive positioning for SYH2072, the triple\u2011combo therapy, and SYH2069. Actual results may differ materially due to clinical trial outcomes, regulatory review timelines, competitive responses, and market access policies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Limited (HKG: 1093) announced that three drug candidates\u2014SYH2072 (aldosterone synthase inhibitor), Priglitin\/Dapagliflozin\/Metformin&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52279,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,171,39,108,855,4361,86],"class_list":["post-52278","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-cspc-pharmaceutical","tag-diabetes","tag-high-blood-pressure","tag-hkg-1093","tag-hot-targets","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC Pharmaceutical Receives IND Approvals for GLP-1\/GIP Agonist and Triple-Combo Diabetes Drug - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that three drug candidates\u2014SYH2072 (aldosterone synthase inhibitor), Priglitin\/Dapagliflozin\/Metformin triple\u2011combination SR tablets, and SYH2069 (GLP\u20111\/GIP dual\u2011biased agonist)\u2014have received Clinical Trial Approval (IND) from China\u2019s National Medical Products Administration (NMPA), advancing a diversified pipeline spanning hypertension, diabetes, and obesity.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52278\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC Pharmaceutical Receives IND Approvals for GLP-1\/GIP Agonist and Triple-Combo Diabetes Drug\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that three drug candidates\u2014SYH2072 (aldosterone synthase inhibitor), Priglitin\/Dapagliflozin\/Metformin triple\u2011combination SR tablets, and SYH2069 (GLP\u20111\/GIP dual\u2011biased agonist)\u2014have received Clinical Trial Approval (IND) from China\u2019s National Medical Products Administration (NMPA), advancing a diversified pipeline spanning hypertension, diabetes, and obesity.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52278\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-30T13:20:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-30T13:20:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3004-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52278#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52278\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC Pharmaceutical Receives IND Approvals for GLP-1\\\/GIP Agonist and Triple-Combo Diabetes Drug\",\"datePublished\":\"2025-12-30T13:20:24+00:00\",\"dateModified\":\"2025-12-30T13:20:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52278\"},\"wordCount\":711,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52278#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3004-1.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CSPC Pharmaceutical\",\"Diabetes\",\"High blood pressure\",\"HKG: 1093\",\"Hot targets\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52278#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52278\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52278\",\"name\":\"CSPC Pharmaceutical Receives IND Approvals for GLP-1\\\/GIP Agonist and Triple-Combo Diabetes Drug - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52278#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52278#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3004-1.webp\",\"datePublished\":\"2025-12-30T13:20:24+00:00\",\"dateModified\":\"2025-12-30T13:20:25+00:00\",\"description\":\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that three drug candidates\u2014SYH2072 (aldosterone synthase inhibitor), Priglitin\\\/Dapagliflozin\\\/Metformin triple\u2011combination SR tablets, and SYH2069 (GLP\u20111\\\/GIP dual\u2011biased agonist)\u2014have received Clinical Trial Approval (IND) from China\u2019s National Medical Products Administration (NMPA), advancing a diversified pipeline spanning hypertension, diabetes, and obesity.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52278#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52278\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52278#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3004-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3004-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"CSPC Pharmaceutical Receives IND Approvals for GLP-1\\\/GIP Agonist and Triple-Combo Diabetes Drug\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52278#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC Pharmaceutical Receives IND Approvals for GLP-1\\\/GIP Agonist and Triple-Combo Diabetes Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC Pharmaceutical Receives IND Approvals for GLP-1\/GIP Agonist and Triple-Combo Diabetes Drug - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that three drug candidates\u2014SYH2072 (aldosterone synthase inhibitor), Priglitin\/Dapagliflozin\/Metformin triple\u2011combination SR tablets, and SYH2069 (GLP\u20111\/GIP dual\u2011biased agonist)\u2014have received Clinical Trial Approval (IND) from China\u2019s National Medical Products Administration (NMPA), advancing a diversified pipeline spanning hypertension, diabetes, and obesity.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52278","og_locale":"en_US","og_type":"article","og_title":"CSPC Pharmaceutical Receives IND Approvals for GLP-1\/GIP Agonist and Triple-Combo Diabetes Drug","og_description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that three drug candidates\u2014SYH2072 (aldosterone synthase inhibitor), Priglitin\/Dapagliflozin\/Metformin triple\u2011combination SR tablets, and SYH2069 (GLP\u20111\/GIP dual\u2011biased agonist)\u2014have received Clinical Trial Approval (IND) from China\u2019s National Medical Products Administration (NMPA), advancing a diversified pipeline spanning hypertension, diabetes, and obesity.","og_url":"https:\/\/flcube.com\/?p=52278","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-30T13:20:24+00:00","article_modified_time":"2025-12-30T13:20:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3004-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52278#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52278"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC Pharmaceutical Receives IND Approvals for GLP-1\/GIP Agonist and Triple-Combo Diabetes Drug","datePublished":"2025-12-30T13:20:24+00:00","dateModified":"2025-12-30T13:20:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52278"},"wordCount":711,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52278#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3004-1.webp","keywords":["Clinical trial approval \/ initiation","CSPC Pharmaceutical","Diabetes","High blood pressure","HKG: 1093","Hot targets","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52278#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52278","url":"https:\/\/flcube.com\/?p=52278","name":"CSPC Pharmaceutical Receives IND Approvals for GLP-1\/GIP Agonist and Triple-Combo Diabetes Drug - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52278#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52278#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3004-1.webp","datePublished":"2025-12-30T13:20:24+00:00","dateModified":"2025-12-30T13:20:25+00:00","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that three drug candidates\u2014SYH2072 (aldosterone synthase inhibitor), Priglitin\/Dapagliflozin\/Metformin triple\u2011combination SR tablets, and SYH2069 (GLP\u20111\/GIP dual\u2011biased agonist)\u2014have received Clinical Trial Approval (IND) from China\u2019s National Medical Products Administration (NMPA), advancing a diversified pipeline spanning hypertension, diabetes, and obesity.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52278#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52278"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52278#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3004-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3004-1.webp","width":1080,"height":608,"caption":"CSPC Pharmaceutical Receives IND Approvals for GLP-1\/GIP Agonist and Triple-Combo Diabetes Drug"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52278#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC Pharmaceutical Receives IND Approvals for GLP-1\/GIP Agonist and Triple-Combo Diabetes Drug"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3004-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52278","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52278"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52278\/revisions"}],"predecessor-version":[{"id":52280,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52278\/revisions\/52280"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52279"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52278"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52278"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52278"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}